The eczema field has spent a decade quieting inflammation. Triveni Bio is going after the leaky barrier that lets the inflammation start.
In a lab off Coolidge Avenue in Watertown, Massachusetts, roughly 54 people are doing something most biotechs their age only dream about: dosing patients. Triveni Bio's lead antibody, TRIV-509, is in a global Phase 2 proof-of-concept study for atopic dermatitis - the chronic, maddening, skin-cracking condition most people call eczema. The company is barely old enough to have a holiday party tradition. It has already raised about $223 million.
Triveni is a clinical-stage biotechnology company. That phrase does a lot of quiet work. It means the science has left the whiteboard and entered human beings. It means the stakes are now measured in trial readouts, not slide decks. And it means the central question - can you treat eczema by fixing the skin's broken barrier instead of just calming the angry immune system behind it - is no longer hypothetical.
Atopic dermatitis is common, and it is miserable. For years, the best drugs - led by the blockbuster Dupixent - have worked by blocking inflammatory signals like IL-4 and IL-13. They help a lot of people. They also leave a lot of people behind, and they share an awkward ceiling: a meaningful share of patients never get fully clear skin.
Triveni's read of the biology is contrarian in a useful way. Inflammation, the company argues, is partly a symptom. Underneath it sits a structural failure - a skin barrier that leaks, lets irritants in, and keeps the immune system permanently irritated. Two enzymes, kallikrein 5 and kallikrein 7, sit at the center of that failure, snipping away at the proteins that hold the barrier together. Calm the immune system all you want; if the barrier stays broken, the fire keeps relighting.
Kallikreins 5 and 7 are proteases - molecular scissors - that, when overactive, degrade the skin barrier and amplify inflammation in atopic dermatitis. Human genetics points to them as a root cause, not a side effect. Triveni's drugs aim to inhibit the active forms specifically.
Triveni Bio did not start from a blank page. It started from a merger - which is either a poetic origin for a company named after a confluence, or a tidy bit of branding after the fact. In 2023 two early-stage biotechs combined: Amagma Therapeutics, founded by serial antibody entrepreneur Tillman Gerngross and stem-cell biologist Leonard Zon with backing from Polaris, and Modify Therapeutics, founded and seeded by Atlas Venture.
The logic was less romantic and more practical. One side brought antibody engineering and target biology. The other brought a complementary approach to modifying disease. Put together, you get Triveni's stated three pillars: a genetics-informed approach to picking targets, advanced antibody engineering to drug them, and a willingness to chase novel biology that bigger players had skipped.
Leading the combined company is CEO Vishal Patel, who holds a PhD in biological chemistry and molecular pharmacology from Harvard and an MBA from MIT, with prior stops at Flagship Pioneering, Novartis, and Merck KGaA. Founding scientist and Chief Scientific Officer Jennifer Dovey - two decades across Amgen, Biogen, and Celgene in epithelial disease biology - has been there since day one.
Triveni emerges from the Amagma + Modify merger, co-led by Atlas Venture and Cormorant, to chase genetics-informed I&I medicines.
Goldman Sachs Alternatives leads, with Fidelity and Deep Track joining existing backers - more money than the Series A, less than a year later.
TRIV-509 doses its first healthy volunteers, alongside preclinical data presentations validating KLK5/7 biology.
First subject dosed in the global Phase 2 proof-of-concept study; translational data shown at the EADV Congress in real patient samples.
The next-generation bispecific - KLK5/7 inhibition plus IL-13 blockade in one molecule - is slated to enter trials.
TRIV-509 is the headline act: a first-in-class, dual-specific, half-life-extended monoclonal antibody that inhibits the active forms of kallikrein 5 and 7. In plain terms - a precision tool designed to stop the two enzymes from shredding the skin barrier, dosed infrequently because it's engineered to stick around. In preclinical models, Triveni says it outperformed IL-4R inhibition, the mechanism behind today's market leader.
Then there's the sequel. TRIV-573 is a bispecific antibody that does two jobs at once: inhibit KLK5/7 to repair the barrier and block IL-13 to dampen inflammation. It's the "fix the fire and the smoke" molecule, and it's expected to reach the clinic around the second quarter of 2026. If TRIV-509 proves the barrier thesis, TRIV-573 is the attempt to combine it with the inflammation playbook everyone already trusts.
TRIV-509: anti-KLK5/7 monoclonal, Phase 2, atopic dermatitis.
TRIV-573: KLK5/7 + IL-13 bispecific, clinic expected ~Q2 2026.
In a biotech market where many startups struggled to raise at all, Triveni did the unusual thing: its second round was bigger than its first, and it arrived fast. Here's the money, by round.
Bars scaled to total raised. Figures from company announcements and press coverage; "total" includes prior seed/predecessor capital.
Fundraising is a vote of confidence, not a verdict. The real evidence Triveni has put on the board is closer to the science. At the 2025 EADV Congress - dermatology's big annual gathering - the company presented translational data showing its novel KLK5/7 biology playing out in actual patient samples, not just mouse models. That matters: plenty of elegant theories die in the gap between animals and humans.
The investor roster reads like a who's who of crossover biotech money: Atlas Venture, Cormorant, OrbiMed, Viking Global, Invus, and Polaris from the early days, joined by Goldman Sachs Alternatives, Fidelity, and Deep Track Capital. These are not tourists. They tend to show up when the preclinical and early-clinical data hold together.
Triveni states its vision plainly: "We bring hope to patients by tackling the underlying biology of their disease." Stripped of the warmth, it's a strategy statement. The company's whole bet is that going one layer deeper - genetics to target, target to antibody, antibody to barrier - produces medicines that clear the ceiling current drugs hit.
Its stated values are the usual biotech quartet done with slightly more self-awareness: Bold & Rigorous, Collaborative, Kind, and Patient Impact. Leadership talks about psychological safety and data-backed argument in the same breath, which is either refreshingly honest or refreshingly normal - your call.
Atopic dermatitis is the proving ground, not the destination. Triveni's own language - "for I&I and beyond" - signals the larger ambition: if a genetics-informed, barrier-first approach works in eczema, the same playbook could extend to other immune and inflammatory diseases where the field has been treating smoke for years.
That's the upside. The honest downside is that biology is unsentimental, and Phase 2 is where confident theses meet inconvenient data. Triveni has the money, the targets, and the team. What it does not yet have is a definitive human efficacy readout. Everything the company is - the confluence, the $223 million, the contrarian bet on the barrier - now funnels toward that single question.
Back in that Watertown lab, the question that used to be hypothetical is now being asked of real patients, one dose at a time. The leaky barrier had a decade-long head start. Triveni Bio is the company betting it can close the gap - and, soon, the data gets to vote.